ABSTRACT: Transient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels. TRPV4 is expressed in the vascular endothelium in the lung and regulates the integrity of the alveolar septal barrier. Increased pulmonary vascular pressure evokes TRPV4-dependent pulmonary edema, and therefore, inhibition of TRPV4 represents a novel approach for the treatment of pulmonary edema associated with conditions such as congestive heart failure. Herein we report the discovery of an orally active, potent, and selective TRPV4 blocker, 3-(1,4′-bipiperidin-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide (GSK2193874, 28) after addressing an unexpected off-target cardiovascular liability observed from in vivo studies. GSK2193874 is a selective tool for elucidating TRPV4 biology both in vitro and in vivo.
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ABSTRACT: Transient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels. TRPV4 is expressed in the vascular endothelium in the lung and regulates the integrity of the alveolar septal barrier. Increased pulmonary vascular pressure evokes TRPV4-dependent pulmonary edema, and therefore, inhibition of TRPV4 represents a novel approach for the treatment of pulmonary edema associated with conditions such as congestive heart failure. Herein we report the discovery of an orally active, potent, and selective TRPV4 blocker, 3-(1,4′-bipiperidin-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide (GSK2193874, 28) after addressing an unexpected off-target cardiovascular liability observed from in vivo studies. GSK2193874 is a selective tool for elucidating TRPV4 biology both in vitro and in vivo. KEYWORDS: GSK2193874, TRPV4, TRPV4 antagonist, TRPV4 inhibitor, congestive heart failure, L-type channel inhibition T ransient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels and is activated by heat, hypotonicity, and physical stress. 1−3 TRPV4 is expressed in numerous cell types, including endothelial cells of the lung where it can mediate Ca 2+ entry. 4 TRPV4 regulates the integrity of the alveolar barrier in the lung and increases barrier permeability when activated, as demonstrated in response to the increased vascular and/or airway pressure. 5 Pharmacological activation of TRPV4 with a small molecule TRPV4 agonist results in contraction of cultured endothelial cells and pulmonary edema associated with cardiovascular collapse in vivo. 6, 7 Congestive heart failure patients have a decreased ability of the left ventricle to pump blood into the peripheral circulatory system. This results in left ventricular dilation and a concomitant increase in pulmonary vascular pressure that drives development of pulmonary edema. Therefore, TRPV4 inhibition represents a potential novel approach for the treatment of pulmonary edema associated with congestive heart failure. 8 TRPV4 also has been implicated in many other disease conditions, including neurogenic pulmonary edema, chronic obstructive pulmonary disorder (COPD), acute lung injury, 9 acute respiratory distress syndrome (ARDS), overactive urinary bladder, pain, genetic motor neuron disorders, cardiovascular disease, and bone related disorders. 8 At the onset of our lead optimization efforts, few small molecule TRPV4 blockers had been reported, and none were suitable for oral dosing. Hydra Biosciences had reported a TRPV4 antagonist HC-067047 with human, rat, and mouse in vitro TRPV4 IC 50 s of 48, 133, and 17 nM, respectively ( Figure  1 ). 10 Renovis (Evotec) had reported RN-1734 as a TRPV4 antagonist with modest potency (human, rat, and mouse TRPV4 IC 50 s of 2.3, 3.2, and 5.9 μM, respectively) ( Figure  1 ). 11 Therefore, discovery of a potent and selective TRPV4 blocker of utility for in vivo studies was highly desirable to further understand the complexity of TRPV4 biology. 12 Herein we report the discovery of an orally active, potent, and selective TRPV4 blocker, 3-(1,4′-bipiperidin-1′-ylmethyl)-
GSK2193874 is an excellent tool for further understanding the biology of TRPV4 both in vitro and in vivo. 8 It is worth noting that, after our discovery of GSK2193874, several orally bioavailable TRPV4 tools have been reported (Figure 1 ). These included Pfizer's azetidine-linked compound, 13 GSK's piperidinyl-benzimidazole compound, 14 Renovis' RN-1665 and RN-9893, 15 and Shionogi's aminothiazole compound. 16, 17 Quinoline hit 1a was identified as a TRPV4 blocker from high throughput screening (Figure 2 ). Compound 1a has modest TRPV4 potency with human and rat TRPV4 IC 50 of 2 and 0.3 μM, respectively, in a FLIPR assay in HEK293 cells. However, it is a potent neurokinin NK2 and NK3 dual inhibitor with IC 50 of 100 and 8 nM, respectively, in FLIPR binding assays. Moreover, 1a has poor pharmacokinetic properties with high clearance (CL = 52 mL/min/kg) in rats. As our primary goal was to validate TRPV4 as a pharmacologically relevant target with a potent and selective TRPV4 inhibitor that could be dosed orally and chronically in rodents, our lead optimization effort was focused on improving TRPV4 potency, removing NK2/3 activity, reducing in vivo clearance, and improving oral exposure in rats.
We divided quinoline 1a into four regions for structure− activity relationship (SAR) exploration ( Figure 2 ): 2-aryl substitution (R 1 ), amine modification (R 2 ), benzyl amide modification (R 3 , R 3a ), and quinoline substitution (R 4 ). Quinoline derivatives were synthesized using standard conditions as described in Scheme 1.
18,19 3-Methyl-2-phenyl-4-quinolinecarboxylic acid 2 was prepared by treatment of the appropriately substituted 1H-indole-2,3-dione and ethyl aryl ketone with KOH in refluxing ethanol. Alternatively, compound 2 was prepared by treatment of the appropriately substituted aniline with the appropriately substituted benzaldehyde and 2-oxobutanoic acid. Esterification of acid 2 resulted in the substituted methyl 3-methyl-2-phenyl-4-quinolinecarboxylate, which was then treated with N-bromosuccinimide and benzoyl peroxide to form an appropriately substituted bromomethyl quinoline. Subsequent displacement of the bromomethyl quinoline with an appropriately substituted piperidine in acetonitrile afforded the corresponding tertiary amine 3. The methyl ester was then hydrolyzed to acid by treatment with KOH in methanol/water. Coupling of the acid with an appropriately substituted benzylamine under standard conditions, for example, EDC/HOBT or T3P, provided quinoline derivatives.
First we focused on the aryl substitution on the 2-position of the quinoline, as this position was known to be sensitive to NK2 and NK3 activity. Substitution of electron-donating groups such as Me and OMe at 4-position (6, 7) or OMe at 3-position (11) of the phenyl ring maintained TRPV4 potency (Table 1 ). Methyl at 3-position (10) of the phenyl ring improved human and rat TRPV4 potency over compound 1a by 4-and 24-fold, respectively. Interestingly substitution of electron-withdrawing groups such as Cl and CF 3 in both positions (4, 5, 8, 9a ) improved human and rat TRPV4 potency by up to 25-and 128-fold, respectively, over unsubstituted quinoline hit 1a. 3-CF 3 compound (9a) is the 
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Compound 9a was evaluated for NK2 and NK3 selectivity, and as expected, 9a has reduced NK2 and NK3 activity with IC 50 s of 1.3 and 2.5 μM, respectively, representing ≥520-fold selectivity over rat TRPV4 potency. Next we evaluated whether there was a stereochemistry preference for binding to TRPV4. Both R-and S-enantiomers for compounds 1 and 9 were synthesized using enantiomerically pure benzyl amines. As shown in Table 2 , there was no significant stereopreference when R 1 is H (1a vs 1b) . Surprisingly, when R 1 is 3-CF 3 , the (S)-enantiomer (9a) was 25-and 160-fold more potent than the corresponding (R)-enantiomer (9b) in human and rat TRPV4 respectively, demonstrating a stereopreference for (S)-enantiomer.
We then evaluated the SAR around piperidine substitution while keeping R 1 as 3-CF 3 and R 3 as S-Me. Piperidine− piperidine analogue (9a) and piperidine−morpholine derivative (14) had optimal TRPV4 potency ( Table 3 ). The terminal piperidine or morpholine was important for TRPV4 activity as compounds without those moieties have reduced TRPV4 activities (12, 13, 15, and 16) .
Since chirality at the α position of benzyl amide (R 3 ) played an important role in TRPV4 potency (Table 2) , we explored additional SAR at that region. As shown in Table 4 , increasing size of the R 3 group from methyl to ethyl and isopropyl decreased TRPV4 potency (9a, 18, 19). Interestingly when R 3 or R 3a is CF 3 , the potency difference for these two analogues (20 and 21) was not as significant as the methyl analogues (9a and 9b). Nonchiral benzyl amides were synthesized to understand stereochemistry preference (17, 22, and 23). The unsubstituted benzyl amide (17) and dimethyl benzyl amide (22) maintained modest TRPV4 potency. Interestingly the cyclopropyl benzyl amide (23) possessed superior TRPV4 potency as 9a and 20 analogues.
Quinoline substitution (R 4 ) was then examined. A variety of substitutions were generally tolerated. Exemplar data for substitutions at the 6-or 7-position are shown in Table 5 . In general, compounds with 7-ethoxy substitution (27 and 30) are more potent in the human TRPV4 assay than the corresponding 7-methoxy analogues (26 and 29). Electronwithdrawing groups such as bromo are tolerated at both 6-and 7-positions (24, 25, and 28). Interestingly all substitutions maintained similar rat TRPV4 potency.
Among all the analogues that were synthesized and evaluated, 9a represented an exemplar tool compound with excellent rodent TRPV4 activity. Compound 9a was evaluated in a PK study in rat and found to have reduced clearance [CL = 25 mL/ min/kg) and significantly improved oral bioavailability (∼100% F) and exposure (DNAUC = 0.8 μg·h/mL/(mg/kg)] in Sprague−Dawley (SD) rats. Next we assessed selectivity of 9a against a panel of cardiac ion channels. Compound 9a was evaluated against hERG (PatchXpress), CaV1.2 (PatchXpress), and NaV1.5 (IonWorks) and found to have IC 50 s of 1.2, 4.5, and 40 μM, respectively, representing ≥480-fold selectivity over rat TRPV4 potency. Based on the potency, selectivity, and PK, 9a was progressed as the first TRPV4 inhibitor for in vivo evaluation.
Compound 9a was evaluated in an anesthetized dog CV study monitoring blood pressure (BP), heart rate (HR), cardiac output, and left ventricular (LV) function. Dogs were pretreated with 1 and 3 mg/kg of 9a dosed intravenously (n = 4). QTc prolongation was observed with compound treatment, consistent with hERG inhibition measured in vitro (IC 50 = 1.2 μM). However, 9a reduced BP, HR, cardiac output, and LV function unexpectedly at 3 mg/kg with C max of ∼20 μM 
Letter (free fraction of 0.94 μM). No effect was observed at 1 mg/kg with C max of ∼7 μM (free fraction of ∼0.3 μM).
To understand if the depressor effect of 9a observed in dog was a TRPV4 mechanism-based or an off-target effect, 9a was administered to TRPV4 KO and WT mice while monitoring BP and HR. Compound 9a was dosed at 30 mg/kg via an iv infusion reaching a terminal plasma concentration of 10−11 μM. As observed in dog, BP and HR were reduced with 9a administration. The responses were similar in KO and WT mice, suggesting 9a possesses off-target activity that contributes to the reduction in BP and HR.
To investigate what off-target activity might contribute to the reduction in BP and HR, we evaluated 9a in a number of assays including rabbit ventricular wedge, HCN4 (pace maker channel), CaV1.2 (L-type channel), CaV2.2 (N-type channel), CaV3.2 (T-type channel), and in vitro contractility in mouse isolated aorta and right atria assays. Based on the overall results, we concluded that the off-target effect observed with 9a was likely due to frequency-dependent L-type channel inhibition with an IC 30 of 1.7 μM at 0.1 Hz and an IC 30 of 0.12 μM at 2 Hz. Two hertz (i.e., 120 beats per minute) is considered to be more physiological relevant than the 0.1 Hz. 20 Minimal or no activities were observed with 9a in all other assays evaluated.
In order to further understand the SAR relating to frequencydependent L-type channel inhibition, a set of structurally diverse quinolines with potent TRPV4 potency was evaluated for L-type channel inhibition using electrophysiology patch assay. Interestingly substitution at the quinoline improves the L-type channel selectivity. A shown in Table 6 , 27 and 28 showed significant improvement in L-type selectivity over 9a and a lack of frequency dependence. Upon further selectivity profiling, we identified 27 as a PXR activator with EC 50 of 1.3 μM, while 28 is not.
The pharmacokinetic (PK) properties for compound 28 were evaluated in both rat and dog and found to have half-lives and oral exposure suitable for oral dosing in chronic animal models (Rat PK: iv CL = 7.3 mL/min/kg, po t 1/2 = 10 h, %F = 31. Dog PK: iv CL = 6.9 mL/min/kg, po t 1/2 = 31 h, %F = 53). Compound 28 was profiled against TRP channels and was selective against TRPV1, TRPA1, TRPC3, TRPC6, and TRPM8 (IC 50 > 25 μM). In addition, 28 showed no blood pressure or heart rate effect in rats when dose up to 30 mg/kg. 8 GSK2193874 (28) is the first-in-class orally bioavailable TRPV4 inhibitor that demonstrated ability to improve pulmonary functions in a number of heart failure models. 8 In summary, starting from the quinoline screening hit 1a, a lead optimization effort identified 9a as a potential in vivo tool compound. Unfortunately 9a exhibited unexpected hemodynamic effect in dogs. By evaluating 9a in various in vitro cardiac channel assays and in vitro contractility assays in mouse isolated aorta and right atria, we concluded that the off-target effect observed with 9a was likely due to frequency-dependent L-type channel inhibition. Further lead optimization resulted in the discovery of GSK2193874 (28), a highly potent, selective, and orally active inhibitor of the TRPV4 channel. GSK2193874 is an excellent in vitro and in vivo tool for target validation studies probing the biology of TRPV4. Additional pharmacology data of GSK2193874 including TRPV4 potency across species, potency against different TRPV4 stimuli, selectivity data on CEREP panel, and activities in pulmonary edema and heart failure models had been disclosed by Thorneloe et al. 8 Further SAR optimization leading to the identification of the preclinical candidates will be reported in due course.
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